Skip to main content
. 2022 Sep 28;23(19):11451. doi: 10.3390/ijms231911451

Figure 2.

Figure 2

Associations of changes in systemic levels of Hsp90 and selected inflammatory cytokines/chemokines in patients with idiopathic inflammatory myopathies treated with standard-of-care pharmacotherapy (control group, CG, n = 23) or with additional non-pharmacological intervention (intervention group, IG, n = 27) for 24 weeks. Lower baseline plasma Hsp90 levels in IG predicted an increase in serum IL-10 (A) and a decrease in MIP-1β (B) over weeks 0–24. (C) Changes in plasma Hsp90 levels in IG over weeks 0–24 correlated positively with changes in serum IL-6 over weeks 0–24. Changes in plasma Hsp90 levels in IG over weeks 0–12 correlated positively with changes in serum IL-2 (D) and negatively with MIP-1β (E) over weeks 0–24. (F) Lower baseline plasma Hsp90 levels in CG predicted a decrease in serum IL-10 over weeks 0–24. Changes in plasma Hsp90 levels in CG over weeks 0–24 correlated positively with changes in serum IL-8 (G) and TNF (H) over weeks 0–24. (I) Changes in plasma Hsp90 levels in CG over weeks 0–12 correlated positively with changes in serum IL-7 over weeks 0–24. W, week.